Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Capital Employed (2016 - 2026)

Insight Molecular Diagnostics' Return on Capital Employed history spans 6 years, with the latest figure at 224.51% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 8998.0% to 224.51% in Q4 2025 year-over-year; TTM through Dec 2025 was 224.51%, a 8998.0% decrease, with the full-year FY2025 number at 278.7%, down 15077.0% from a year prior.
  • Return on Capital Employed hit 224.51% in Q4 2025 for Insight Molecular Diagnostics, down from 154.97% in the prior quarter.
  • Over the last five years, Return on Capital Employed for IMDX hit a ceiling of 11.13% in Q1 2023 and a floor of 224.51% in Q4 2025.
  • Historically, Return on Capital Employed has averaged 67.62% across 5 years, with a median of 43.44% in 2022.
  • Biggest five-year swings in Return on Capital Employed: skyrocketed 3627bps in 2023 and later crashed -9915bps in 2024.
  • Tracing IMDX's Return on Capital Employed over 5 years: stood at 49.53% in 2021, then soared by 69bps to 15.43% in 2022, then plummeted by -129bps to 35.38% in 2023, then plummeted by -280bps to 134.53% in 2024, then tumbled by -67bps to 224.51% in 2025.
  • Business Quant data shows Return on Capital Employed for IMDX at 224.51% in Q4 2025, 154.97% in Q3 2025, and 130.74% in Q2 2025.